HC Wainwright raised their FY2025 EPS estimates for shares of Opthea in a note issued to investors on Tuesday, March 25th. HC ...

The firm’s unlisted high-conviction equities strategy is more than 44 per cent invested in healthcare stocks. The biotech has ...

Opthea was making preparations for the potential launch of a new eye disease drug onto the market. | A month ago, Opthea was ...

Analysts at Leerink Partnrs decreased their FY2025 earnings estimates for shares of Opthea in a report issued on Monday, ...

The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

Opthea's Phase 3 COAST trial for wet AMD did not meet its primary endpoint, raising financial concerns as the company faces ...

From Phil King’s Regal Partners to Russel Pillemer’s Pengana Capital, fund managers loved vision treatment hopeful Opthea.

Biotechnology firm Opthea has warned investors its solvency is in question after the failure of a major clinical trial into ...

Trading in shares of Opthea remains halted in the U.S. and Australia after the clinical-stage biopharmaceutical company said its lead product candidate, sozinibercept, failed in a late-stage study in ...

A failed clinical trial has rattled investors. The post Amid fears of collapse, what's happening with Opthea ASX shares today ...

Opthea (OPT) announced results from its global Phase 3 clinical trial COAST in patients with wet AMD. The global COAST Phase 3 trial evaluated ...

COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52Opthea considering impact of negative trial ...